Smart Immune appoints key new members to its Board of Directors
February 16, 2024 02:00 ET
|
Smart Immune
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell...
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
December 04, 2023 06:46 ET
|
Smart Immune
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage...
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform
November 10, 2023 05:52 ET
|
Smart Immune
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform Clinical-stage T-cell progenitor therapy aims to re-arm the immune system against cancer and infection New class of...
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023
November 02, 2023 09:00 ET
|
Smart Immune
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
Smart Immune Showcases Data and Presentations at ESGCT
October 12, 2023 06:00 ET
|
Smart Immune
PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the...
Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
September 27, 2023 02:00 ET
|
Smart Immune
No safety concerns in first two patients treatedDesigned to accelerate T-cell reconstitution following haploidentical Hematopoietic Stem Cell Transplantation (HSCT) with post-transplant...
Deux premiers patients atteints de leucémie ont reçu la thérapie SMART101 de Smart Immune dans le cadre de l'essai ReSET-02 de phase I/II
September 27, 2023 02:00 ET
|
Smart Immune
Aucune toxicité observée chez les deux premiers patients traités SMART101 est conçu pour accélérer la reconstitution immunitaire après une greffe de cellules souches haplo-identique suivie d’un...
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
May 11, 2023 11:58 ET
|
Smart Immune
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform
April 17, 2023 01:00 ET
|
Smart Immune
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new funding from the Gates Foundation will advance a Phase 1/2 clinical trial of an...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
March 30, 2023 07:00 ET
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...